Findings related to effectiveness ( treatment discontinuation , quality of life , and neurocognitive improvements ) were generally consistent with those observed in non-Chinese population s. No new safety signals specific for Chinese population s were raised for olanzapine .
Chinese and non-Chinese population s with schizophrenia or bipolar disorder treated with olanzapine display broadly similar responses .
BACKGROUND Despite the burden of schizophrenia and bipolar disorder in the Chinese population , country-specific data to guide practitioners regarding antipsychotic therapy are lacking .
Efficacy and tolerability of ziprasidone vs. olanzapine in naive first-episode schizophrenia: a 6-week, randomized, open-label, flexible-dose study.
INTRODUCTION Although some previous studies have compared the 2 medicines , ziprasidone and olanzapine most selected chronic patients as subjects . Therefore , the present study was design ed to compare the efficacy and safety of ziprasidone vs. olanzapine in naive first-episode schizophrenia . METHODS 80 patients were r and omly assigned to a 6-week treatment either with 80 - 160 mg/day of ziprasidone or 10 - 20 mg/day of olanzapine . The primary efficacy measurements were the Positive and Negative Syndrome Scale and Clinical Global Impression-severity scale scores . The second efficacy measurement was the response rate of treatment . Tolerability assessment s were also performed . RESULTS 79 patients completed the trial . The average dose was 127.5 mg/day with ziprasidone and 19.1 mg/day with olanzapine . No significant differences were found between the 2 groups in primary or secondary efficacy measurements at each visit point ( all p>0.05 ) . Body weight significantly increased with olanzapine , and more extrapyramidal symptoms were observed with ziprasidone ( all p<0.05 ) . Both medicines were well tolerated , and no serious adverse events were observed . CONCLUSION Ziprasidone was as effective as olanzapine in short-term treatment for first-episode schizophrenia , and both medicines were well tolerated
Findings related to effectiveness ( treatment discontinuation , quality of life , and neurocognitive improvements ) were generally consistent with those observed in non-Chinese population s. No new safety signals specific for Chinese population s were raised for olanzapine .
Chinese and non-Chinese population s with schizophrenia or bipolar disorder treated with olanzapine display broadly similar responses .
BACKGROUND Despite the burden of schizophrenia and bipolar disorder in the Chinese population , country-specific data to guide practitioners regarding antipsychotic therapy are lacking .